CN110041290A - 2,5- dihydro -1,4,5- sulphur phenodiazine Zhuo and its oxide preparation method - Google Patents

2,5- dihydro -1,4,5- sulphur phenodiazine Zhuo and its oxide preparation method Download PDF

Info

Publication number
CN110041290A
CN110041290A CN201910258698.XA CN201910258698A CN110041290A CN 110041290 A CN110041290 A CN 110041290A CN 201910258698 A CN201910258698 A CN 201910258698A CN 110041290 A CN110041290 A CN 110041290A
Authority
CN
China
Prior art keywords
sulphur
nmr
dihydro
target compound
cdcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910258698.XA
Other languages
Chinese (zh)
Inventor
程斌
李运通
翟宏斌
张昕平
李慧
胡汉巍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lanzhou University
Original Assignee
Lanzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanzhou University filed Critical Lanzhou University
Priority to CN201910258698.XA priority Critical patent/CN110041290A/en
Publication of CN110041290A publication Critical patent/CN110041290A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36Seven-membered rings

Abstract

The main purpose of the present invention is to provide the preparation methods of a kind of completely new 2,5- dihydro -1,4,5- sulphur phenodiazine tall and erect (2,5-dihydro-1,4,5-thiadiazepine) and its oxide.The method achieve by alpha-halogenate hydrazone compounds and sulfur-bearing inner salt, under conditions of sodium carbonate makees alkali, synthesis 2 that a step is simple and efficient, 5- dihydro-Isosorbide-5-Nitrae, 5- sulphur phenodiazine are tall and erect, simultaneously by control oxidising agent equivalent, can a step obtain the oxidation product of different oxidation state.It may be a kind of good drug leads molecule in view of such compound, there is good drug research value.

Description

2,5- dihydro -1,4,5- sulphur phenodiazine Zhuo and its oxide preparation method
Technical field
The invention belongs to the field of chemical synthesis, and in particular to 2,5- of one kind dihydro-Isosorbide-5-Nitrae, 5- sulphur phenodiazine Zhuo (2,5- ) and its preparation method of oxide dihydro-1,4,5-thiadiazepine.
Background technique
Nitrogen and element sulphur are widely present in nature and organism, nitrogenous compound it is representative be exactly day Right organic-biological alkali, has extremely important effect in field of medicaments;Sulfur-containing compound is then widely used in material, drug Even in food.Heptatomic ring pastern bone frame succinctly efficiently constructs heptatomic ring system there are in many natural products and drug molecule skeleton Always one of organic chemist and the emphasis of pharmaceutical chemists research.We are not yet ground by the way that one kind is novel Study carefully the sulfur-bearing inner salt and common alpha-halogenate hydrazone reaction of exploitation, a step is efficiently constructed comprising four substituent groups and three hetero atoms Heptatomic ring system, wherein four substituent groups can be with further progress function dough, to obtain a series of particular functional dough Compound, this kind of molecule are expected to become useful drug leads (Merta, B.D.*and Elattarb, K.M.Seven- membered Rings with Three Heteroatoms:Chemistry of 1,2,5-and 1,4,5- Thiadiazepines,Current Organic Chemistry,2018,22,386-410)。
The sulfur-containing compound of different oxidation states can show different physicochemical property and bioactivity, especially medical Field and advanced material field, the oxidation state for changing element sulphur in sulfur-containing compound tend to significantly improve pharmaceutical activity and material Expect performance, and mutually converting between element sulphur difference oxidation state is the research emphasis of drug pharmacological effect, efficient selective Oxidation sulfur-containing organic compound have great importance.
Summary of the invention
The main purpose of the present invention is to provide a kind of completely new 2,5- dihydro -1,4,5- sulphur phenodiazine Zhuo (2,5- ) and its preparation method of oxide dihydro-1,4,5-thiadiazepine.The method achieve by alpha-halogenate hydrazone class chemical combination Object and sulfur-bearing inner salt, under conditions of sodium carbonate makees alkali, the synthesis 2 that a step is simple and efficient, 5- dihydro-Isosorbide-5-Nitrae, 5- sulphur phenodiazine Zhuo, while only can aoxidize to obtain the oxidation product of different oxidation state by a step by control oxidising agent equivalent.
Compound of the present invention be as in formula 1 I compound represented -2,5- dihydro -1,4,5- sulphur phenodiazine it is tall and erect (2, 5-dihydro-1,4,5-thiadiazepine) and its oxide II and III.
Wherein: R1For substituted aryl substituent group (on phenyl ring replace include 4- methoxyl group, 4- methyl, 4- nitro, 4- cyano, 4- trifluoromethyl, 4- fluorine, 4- chlorine, 4- bromine), 1- naphthyl substituted base, 2- furyl substituent, alkyl substituent, alkenyl group;R2 For acetyl group or tertbutyloxycarbonyl substituent group;R3For methyl substituents or ethyl substituent.
2,5- dihydro -1,4,5- sulphur phenodiazine of the invention tall and erect (2,5-dihydro-1,4,5-thiadiazepine) and its The preparation method of oxide is as shown in Equation 2:
Compound shown in compound shown in general formulae IV, general formula V and powdered sodium carbonate are dissolved in two at room temperature In chloromethane alkane solvents, reactant IV disappears completely, and organic solvent will be removed under reaction mixture reduced pressure, and column chromatographic elution obtains To target compound I, in reactant IV: wherein R1For substituted aryl substituent group, (replace on phenyl ring includes 4- methoxyl group, 4- first Base, 4- nitro, 4- cyano, 4- trifluoromethyl, 4- fluorine, 4- chlorine, 4- bromine), 1- naphthyl substituted base, 2- furyl substituent, alkyl takes Dai Ji, alkenyl group;R2For acetyl group or tertbutyloxycarbonyl substituent group;R3For methyl substituents or ethyl substituent.
The preparation method of target compound II: i.e. by m-CPBA (the m-chloro peroxide of compound shown in general formula I and appropriate equivalent Benzoic acid) it is dissolved in dichloromethane solvent at room temperature, reactant I disappears completely, by reaction mixture reduced pressure Lower removing organic solvent, column chromatographic elution obtain target compound II, in reactant I: wherein R1For substituted aryl substituent group (benzene Replace on ring includes 4- methoxyl group, 4- methyl, 4- nitro, 4- trifluoromethyl, 4- fluorine), 2- furyl substituent, alkyl substituent, Alkenyl group;R2For acetyl group or tertbutyloxycarbonyl substituent group;R3For methyl substituents or ethyl substituent.
The preparation method of target compound III: i.e. by compound shown in general formula I and appropriate excessive m-CPBA (m-chloro peroxide Benzoic acid) it is dissolved in dichloromethane solvent at room temperature, reactant I disappears completely, by reaction mixture reduced pressure Lower removing organic solvent, column chromatographic elution obtain target compound III, in reactant I: wherein R1For substituted aryl substituent group (benzene Replace on ring includes 4- methoxyl group, 4- methyl, 4- trifluoromethyl, 4- fluorine), 2- furyl substituent, alkyl substituent, alkenyl substitution Base;R2For acetyl group or tertbutyloxycarbonyl substituent group;R3For methyl substituents.
Currently preferred 2,5- dihydro -1,4,5- sulphur phenodiazine is tall and erect (2,5-dihydro-1,4,5-thiadiazepine) Preparation method be to use sodium carbonate as alkali, using methylene chloride as solvent.
Further, currently preferred preparation method is: compounds Ⅳ, compound V rub with carbonate reagent when reaction You are IV: V than (i.e. equivalent proportion): sodium carbonate=1.0:1.5:2.0, and dichloromethane solution concentration is 0.1M, i.e., 0.1 mole every It rises.
Further, for currently preferred preparation method in silica gel column chromatography, eluent used is petroleum ether and second The mixed solvent of acetoacetic ester, and volume ratio VPetroleum ether:VEthyl acetate=5:1~2:1.
Method of the present invention is the introducing reagent for using a kind of novel organic sulfur-containing inner salt for the first time as sulphur atom, Reagent preparation is convenient, and the foul odour having without commonly using sulfur-bearing regent;Contain in another raw material simultaneously there are two nitrogen-atoms, This makes a step of the invention just construct the heteroatomic heptatomic ring containing there are three, may have good bioactivity, so as to It can obtain a kind of completely new drug leads molecule.
Method of the present invention can be easy to prepare 2,5- dihydro -1,4,5- sulphur phenodiazine Zhuo (2,5-dihydro- Isosorbide-5-Nitrae, 5-thiadiazepine) and its oxide, raw material be easy to get, do not use precious metal reagent, operation is simple, after Processing is convenient, and yield is generally very high, and is not necessarily to inert gas shielding during the preparation process, and reaction condition is mild, can be in room temperature (25 DEG C) go on smoothly reaction, it is easy to accomplish a large amount of preparations.
Detailed description of the invention
Attached drawing 1-6 is respectively the obtained product I -1 of the embodiment of the present invention, II -2 and III -3 nuclear magnetic spectrogram (hydrogen spectrum It is composed with carbon).
Specific embodiment
The present invention is explained below in conjunction with specific embodiment.
It is the most preferred embodiment of prepare compound of the present invention below.In following all examples, nuclear-magnetism spectrum detection passes through 400 and Varian of Varian 300, Bruker 400, JEOL, 600 MHz instrument is in CDCl3、(CD3)2CO or d6-DMSO Middle acquisition.δ value is internal standard relative value (CDCl3Calibrate δ 7.261H NMR and 77.0013C NMR;(CD3)2CO calibrates δ 2.051H NMR and 29.8413C NMR;d6-DMSOδ2.50 1H NMR and 39.5213C NMR).High resolution mass spectrum (HRMS) passes through 4G quadrupole time-of-flight (QTof) mass spectrometer obtains.
Embodiment 1
The reaction equation of embodiment 1, specifically used compounds Ⅳ -1 and compound V -1 and I -1 structure of product are shown in formula 3. Experiment shows that currently preferred alkali is sodium carbonate, and preferred organic solvent is methylene chloride, the highest yield of reaction product Be 98%, best material molar ratio be compounds Ⅳ: compound V: carbonate reagent=1.0:1.5:2.0, solution it is optimal Concentration is 0.1M.
Specific experiment step is: by the compounds Ⅳ -1 of 76mg (0.30mmol, 1.0 equivalents) and 114mg (0.450mmol, 1.5 equivalents) compound V -1 be dissolved in the methylene chloride of 3mL, be added 64mg (0.60mmol, 2.0 equivalents) sodium carbonate, in 25 DEG C of reactions.Thin-layer chromatography monitoring reactant IV -1 has disappeared, and by reaction mixture, rotary evaporation removing is molten under water pump decompression Agent methylene chloride.Residue is with 200-300 mesh silica gel, eluent (volume ratio VPetroleum ether:VEthyl acetate=5:1~2:1) column chromatographs to obtain Compound 102mg shown in I -1, product by nuclear-magnetism (hydrogen spectrum, carbon spectrum), high resolution mass spectrum identification, and I -1 by monocrystalline into one It walks and determines its structure.
Product I -1 is yellow solid, yield 98%;Fusing point: 192.8-193.1 DEG C of1H NMR(400MHz,CDCl3)δ 7.91 (d, J=7.6Hz, 2H), 7.56 (t, J=7.2Hz, 1H), 7.47 (t, J=7.2Hz, 2H), 4.27 (s, 2H), 3.74 (s,3H),3.73(s,3H),2.12(s,3H);13C NMR(100MHz,CDCl3)δ171.0,170.8,163.9,162.9, 132.6,132.2,129.9,129.8,128.9,127.4,53.2,52.7,25.5,21.6;ESI-HRMS m/z calcd for C16H16N2O5S+H+349.0853, found 349.0855. mono-crystalline structures are stored in Cambridge crystal data library, monocrystalline storage Number: CCDC 1885455.
Prepare method and implementation used in the embodiment of other compounds of the invention (chemical compounds I -2 to chemical compounds I -24) Example 1 is identical, and reaction condition is as follows: compounds Ⅳ (0.3mmol), compound V (1.5 equivalent) are dissolved in the methylene chloride of 3mL, Addition sodium carbonate amount is 64mg (0.60mmol, 2.0 equivalents), 25 DEG C of room temperature reactions.
Embodiment 2
The reaction equation of embodiment 2, specifically used chemical compounds I -1 and II -1 structure of product are shown in formula 4.
Specific experiment step is: by the chemical compounds I -1 of 105mg (0.300mmol, 1.0 equivalents) and 61mg (0.30mmol, 1.0 equivalents) m-CPBA (85%, metachloroperbenzoic acid) be dissolved in the methylene chloride of 3mL, in 25 DEG C react.Thin-layer chromatography Monitoring reactant I -1 has disappeared, and reaction mixture is rotated evaporation of solvent methylene chloride under water pump decompression.Residue with 200-300 mesh silica gel, eluent (volume ratio VPetroleum ether:VEthyl acetate=3:1~1:1) column chromatographs to obtain compound 81mg shown in II -1, Its product is by nuclear-magnetism (hydrogen spectrum, carbon spectrum), high resolution mass spectrum identification.
Product II -1 is white solid, yield 74%;Fusing point: 123.9-124.6 DEG C of1H NMR(400MHz,CDCl3)δ 7.91 (d, J=7.2Hz, 2H), 7.56 (t, J=7.2Hz, 1H), 7.48 (t, J=7.2Hz, 2H), 4.49 (d, J=13.6Hz, 1H), 4.30 (d, J=13.2Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 2.38 (s, 3H);13C NMR(100MHz, CDCl3)δ172.5,166.0,163.0,162.3,140.3,134.3,132.5,129.0,127.8,53.5,48.0,22.3, (2C missing);ESI-HRMS m/z calcd for C16H16N2O6S+Na+ 387.0621,found 387.0620.
Prepare method and reality used in the embodiment of other compounds of the invention (compound ii -2 to compound ii -15) Apply that example 2 is identical, and reaction condition is as follows: chemical compounds I (0.3mmo) l and m-CPBA (metachloroperbenzoic acid, 1.0 equivalents) are dissolved in In the methylene chloride of 3mL, 25 DEG C of room temperature reactions.
Embodiment 3
The reaction equation of embodiment 3, specifically used chemical compounds I -1 and III -1 structure of product are shown in formula 5.
Specific experiment step is: by the chemical compounds I -1 of 105mg (0.3mmol, 1.0 equivalents) and 183mg (0.9mmol, 3.0 Equivalent) m-CPBA (85%, metachloroperbenzoic acid) be dissolved in the methylene chloride of 3mL, in 25 DEG C react.Thin-layer chromatography monitoring Reactant I -1 has disappeared, and reaction mixture is diluted with methylene chloride, and the sodium bicarbonate solution 10mL of saturation is added, and water phase is used Methylene chloride extracts three times, merges organic phase, and dry with anhydrous sodium sulfate, and rotary evaporation removes organic molten under water pump decompression Agent methylene chloride.Residue is with 200-300 mesh silica gel, eluent (volume ratio VPetroleum ether:VEthyl acetate=10:1~3:1) column chromatographs To compound 75mg shown in III -1, product is by nuclear-magnetism (hydrogen spectrum, carbon spectrum), high resolution mass spectrum identification, and III -1 by monocrystalline Further determine that its structure.
Product III -1 is white solid, yield 66%;Fusing point: 185.3-185.9 DEG C of1H NMR(400MHz,CDCl3)δ 7.99 (d, J=7.2Hz, 2H), 7.62 (t, J=7.2Hz, 1H), 7.53 (t, J=7.2Hz, 2H), 4.74 (s, 2H), 3.86 (s,3H),3.84(s,3H),2.35(s,3H);13C NMR(100MHz,CDCl3)δ172.6,163.0,161.8,160.4, 142.6,133.2,131.8,129.2,128.3,54.5,53.8,53.7,22.4,(1C missing);ESI-HRMS m/z calcd for C16H16N2O7S+Na+403.0570, found 403.0565. mono-crystalline structures are stored in Cambridge crystal data library, single Crystalline substance storage number: CCDC 1887981.
Prepare method and reality used in the embodiment of other compounds of the invention (compound III -2 to compound III -9) Apply that example 3 is identical, and reaction condition is as follows: chemical compounds I (0.3mmol) and m-CPBA (metachloroperbenzoic acid, 3.0 equivalents) are dissolved in In the methylene chloride of 3mL, 25 DEG C of room temperature reactions.
Products therefrom structure and data are characterized as below:
Product I -2 is yellow solid, yield 89%;Fusing point: 71.8-72.4 DEG C of1H NMR(400MHz,CDCl3)δ 7.87 (d, J=8.8Hz, 2H), 6.95 (d, J=8.8Hz, 2H), 4.24 (s, 2H), 3.84 (s, 3H), 3.73 (s, 3H), 3.71 (s,3H),2.08(s,3H);13C NMR(100MHz,CDCl3)δ170.8,170.7,163.9,163.0,162.9,129.8, 129.7,129.2,124.4,114.2,55.4,53.2,52.7,25.1,21.5;ESI-HRMS m/z calcd for C17H18N2O6S+Na+ 401.0787,found 401.0784.
Product I -3 is yellow solid, yield 86%;Fusing point: 151.7-152.5 DEG C of1H NMR(400MHz,CDCl3)δ 7.83 (d, J=8.4Hz, 2H), 7.30 (d, J=7.6Hz, 2H), 4.28 (s, 2H), 3.77 (s, 3H), 3.75 (s, 3H), 2.43 (s,3H),2.13(s,3H);13C NMR(100MHz,CDCl3)δ171.1,170.8,163.9,162.9,143.0,129.8, 129.7,129.6,129.6,127.4,53.2,52.7,25.3,21.6,21.4.ESI-HRMS m/z calcd for C17H18N2O5S+Na+ 385.0829,found 385.0831.
Product I -4 is yellow solid, yield 81%;Fusing point: 206.7-207.4 DEG C of1H NMR(400MHz,CDCl3)δ 8.35 (d, J=8.8Hz, 2H), 8.08 (d, J=9.2Hz, 2H), 4.26 (s, 2H), 3.79 (s, 6H), 2.20 (s, 3H)13C NMR(100MHz,d6-DMSO)δ171.2,170.0,164.1,162.6,149.6,138.6,130.8,129.2,128.5, 124.0,53.6,52.8,25.2,21.6;ESI-HRMS m/z calcd for C16H15N3O7S+Na+ 416.0523,found 416.0526.
Product I -5 is yellow solid, yield 97%;Fusing point: 194.1-194.7 DEG C of1H NMR(400MHz,CDCl3)δ 8.02 (d, J=8.4Hz, 2H), 7.78 (d, J=8.8Hz, 2H), 4.25 (s, 2H), 3.76 (s, 3H), 3.75 (s, 3H), 2.15 (s,3H);13C NMR(100MHz,CDCl3)δ171.1,168.0,163.8,162.6,137.1,132.6,130.7,129.9, 127.9,117.8,115.4,53.4,52.9,25.8,21.7;ESI-HRMS m/z calcd for C17H15N3O5S+Na+ 396.0625,found 396.0629.
Product I -6 is yellow solid, yield 91%;Fusing point: 173.2-173.6 DEG C of1H NMR(400MHz,CDCl3)δ 8.03 (d, J=8.0Hz, 2H), 7.73 (d, J=8.4Hz, 2H), 4.28 (s, 2H), 3.75 (s, 6H), 2.14 (s, 3H);13C NMR(100MHz,CDCl3) δ 171.1,169.0,163.9,162.8,136.3,133.7 (q, J=32.7Hz), 130.4, 129.8,127.8,125.9 (q, J=3.7Hz), 123.5 (q, J=271.2Hz), 53.3,52.8,25.8,21.6;ESI- HRMS m/z calcd for C17H15F3N2O5S+Na+ 439.0546,found 439.0548.
Product I -7 is yellow solid, yield 92%;Fusing point: 151.9-152.3 DEG C of1H NMR(400MHz,CDCl3)δ 7.96-7.90 (m, 2H), 7.15 (t, J=8.4Hz, 2H), 4.26 (s, 2H), 3.72 (s, 6H), 2.09 (s, 3H);13C NMR (100MHz,CDCl3) δ 170.8,170.1,165.2 (d, J=252.6Hz), 163.8 162.9,129.8,129.8 (d, J= 8.6Hz), 128.6,128.6,116.0 (d, J=21.8Hz), 53.2,52.7,25.4,21.5;ESI-HRMS m/z calcd for C16H15FN2O5S+Na+ 389.0578,found 389.0574.
Product I -8 is yellow solid, yield 82%;Fusing point: 155.7-158.3 DEG C of1H NMR(400MHz,CDCl3)δ 7.85 (d, J=8.4Hz, 2H), 7.44 (d, J=8.8Hz, 2H), 4.25 (s, 2H), 3.74 (s, 6H), 2.10 (s, 3H);13C NMR(100MHz,CDCl3)δ170.9,169.8,163.9,162.8,138.6,131.0,130.0,129.8,129.2, 128.7,53.3,52.8,25.4,21.6;ESI-HRMS m/z calcd for C16H15ClN2O5S+Na+ 405.0282, found 405.0281.
Product I -9 is yellow solid, yield 83%;Fusing point: 144.8-145.2 DEG C of1H NMR(400MHz,CDCl3)δ 7.78 (d, J=8.8Hz, 2H), 7.60 (d, J=8.4Hz, 2H), 4.24 (s, 2H), 3.74 (s, 6H), 2.11 (s, 3H);13C NMR(100MHz,CDCl3)δ170.9,169.9,163.8,162.8,132.2,131.5,130.0,129.7,128.9, 127.1,53.3,52.8,25.4,21.6;ESI-HRMS m/z calcd for C16H15BrN2O5S+Na+ 448.9777, found 448.9778.
Product I -10 is yellow solid, yield 79%;Fusing point: 222.1-222.7 DEG C of1H NMR(400MHz,CDCl3)δ 8.30 (d, J=0.8Hz, 1H), 8.10 (dd, J=8.8,2.0Hz, 1H), 7.92 (d, J=8.4Hz, 2H), 7.89 (d, J= 8.0Hz,1H),7.63-7.54(m,2H),4.40(s,2H),3.79(s,3H),3.76(s,3H),2.18(s,3H);13C NMR (100MHz,CDCl3)δ171.0,170.9,164.0,163.0,135.0,132.6,130.0,129.9,129.8,128.9, 128.9,128.7,128.2,127.8,127.0,123.3,53.3,52.8,25.5,21.7;ESI-HRMS m/z calcd for C20H18N2O5S+Na+ 421.0829,found 421.0828.
Product I -11 is yellow solid, yield 55%;Fusing point: 134.6-135.1 DEG C of1H NMR(400MHz,CDCl3)δ 7.67 (d, J=1.2Hz, 1H), 7.26 (d, J=3.6Hz, 1H), 6.63 (dd, J=3.6,1.6Hz, 1H), 4.23 (s, 2H), 3.77(s,6H),2.13(s,3H);13C NMR(75MHz,CDCl3)δ171.1,164.0,162.8,161.8,146.9, 146.6,130.7,129.8,115.8,112.9,53.3,52.8,24.8,21.6;ESI-HRMS m/z calcd for C14H14N2O6S+Na+ 361.0465,found 361.0464.
Product I -12 is yellow solid, yield 91%;Fusing point: 186.8-187.4 DEG C of1H NMR(400MHz,CDCl3)δ 3.85(s,2H),3.74(s,3H),3.72(s,3H),1.97(s,3H),1.29(s,9H);13C NMR(100MHz,CDCl3)δ 182.6,170.3,163.9,162.9,129.5,129.1,53.2,52.6,39.2,27.6,23.9,21.4;ESI-HRMS m/ z calcd for C14H20N2O5S+Na+ 351.0985,found 351.0984.
Product I -13 is yellow solid, yield 64%;Fusing point: 212.3-212.5 DEG C of1H NMR(400MHz,CDCl3)δ 7.59-7.53 (m, 2H), 7.46-7.39 (m, 3H), 7.30 (d, J=16.4Hz, 1H), 7.00 (d, J=16.4Hz, 1H), 4.13(s,2H),3.77(s,6H),2.11(s,3H);13C NMR(75MHz,CDCl3)δ171.0,170.9,164.0,162.9, 141.1,134.5,130.6,130.3,129.8,129.0,127.8,122.4,53.3,52.8,23.8,21.6;ESI-HRMS m/z calcd for C18H18N2O5S+Na+ 397.0829,found 397.0827.
Product I -14 is yellow solid, yield 89%;Fusing point: 150.2-150.9 DEG C of1H NMR(400MHz,CDCl3)δ 7.91 (d, J=7.2Hz, 2H), 7.54 (t, J=7.2Hz, 1H), 7.47 (t, J=7.6Hz, 2H), 4.25 (s, 2H), 4.23- 4.14 (m, 4H), 2.11 (s, 3H), 1.27 (t, J=7.2Hz, 3H), 1.24 (t, J=6.8Hz, 3H);13C NMR(100MHz, CDCl3)δ170.9,170.8,163.5,162.3,132.7,132.2,130.0,129.9,128.8,127.4,62.5,61.9, 25.5,21.6,13.8,13.7;ESI-HRMS m/z calcd for C18H20N2O5S+H+ 377.1166,found 377.1164.
Product I -15 is yellow solid, yield 93%;Fusing point: 135.3-136.7 DEG C of1H NMR(400MHz,CDCl3)δ 7.88 (d, J=8.0Hz, 2H), 7.52-7.45 (m, 1H), 7.44-7.46 (m, 2H), 3.75 (s, 3H), 3.72 (s, 3H), 1.46(s,9H),(2H missing);13C NMR(100MHz,CDCl3)δ171.2,164.0,163.1,151.4,133.0, 131.8,128.6,127.6,83.0,53.2,52.5,28.0,26.1,(2C missing);ESI-HRMS m/z calcd for C19H22N2O6S+Na+ 429.1091,found 429.1089.
Product I -16 is yellow solid, yield 67%;Fusing point: 57-58 DEG C of1H NMR(400MHz,CDCl3)δ7.86 (d, J=8.8Hz, 2H), 6.92 (d, J=9.2Hz, 2H), 3.83 (s, 3H), 3.77 (s, 3H), 3.73 (s, 3H), 1.47 (s, 9H),(2H missing);13C NMR(100MHz,CDCl3)δ170.7,164.2,163.2,162.7,129.5,125.2, 114.1,83.0,55.4,53.2,52.5,28.1,26.0,(3C missing);ESI-HRMS m/z calcd for C20H24N2O7S+H+ 437.1377,found 437.1371.
Product I -17 is yellow solid, yield 83%;Fusing point: 62-63 DEG C of1H NMR(400MHz,CDCl3)δ7.78 (d, J=8.4Hz, 2H), 7.22 (d, J=8.0Hz, 2H), 3.76 (s, 3H), 3.72 (s, 3H), 2.37 (s, 3H), 1.46 (s, 9H),(2H missing);13C NMR(100MHz,CDCl3)δ171.1,164.1,163.1,151.4,142.4,130.1, 129.3,127.6,82.9,53.1,52.4,28.0,26.0,21.3,(2C missing);ESI-HRMS m/z calcd for C20H24N2O6S+H+ 421.1428,found 421.1427.
Product I -18 is yellow solid, yield 97%;Fusing point: 74-75 DEG C of1H NMR(400MHz,CDCl3)δ8.22 (d, J=8.8Hz, 2H), 8.06 (d, J=8.8Hz, 2H), 3.74 (s, 3H), 3.71 (s, 3H), 1.44 (s, 9H), (2H missing);13C NMR(100MHz,CDCl3)δ169.1,163.8,162.9,151.2,149.5,139.0,130.8, 128.8,128.6,123.7,83.5,53.2,52.6,27.9,26.0;ESI-HRMS m/z calcd for C19H21N3O8S+ Na+ 474.0942,found 474.0941.
Product I -19 is yellow solid, yield 95%;Fusing point: 64-65 DEG C of1H NMR(400MHz,CDCl3)δ8.02 (d, J=8.0Hz, 2H), 7.68 (d, J=8.0Hz, 2H), 3.77 (s, 3H), 3.74 (s, 3H), 1.47 (s, 9H), (2H missing);13C NMR(100MHz,CDCl3) δ 169.9,164.0,163.0,151.4,136.6,133.3 (q, J= 32.6Hz), 131.0,128.8,128.0,125.6 (q, J=3.7Hz), 123.6 (q, J=270.9Hz), 83.4,53.3, 52.6,28.0,26.2;ESI-HRMS m/z calcd for C20H21F3N2O6S+Na+ 497.0965,found 497.0966.
Product I -20 is yellow solid, yield 92%;Fusing point: 74-75 DEG C of1H NMR(400MHz,CDCl3)δ7.92– 7.82(m,2H),7.10–6.99(m,4H),3.72(s,3H),3.68(s,3H),1.42(s,9H),(2H missing);13C NMR(100MHz,CDCl3) δ 170.1,164.8 (d, J=251.6Hz), 163.9,163.0,151.3,130.9,129.8 (d, J =8.8Hz), 129.0 (d, J=2.5Hz), 128.4,115.67 (d, J=21.8Hz), 83.0,53.1,52.4,27.8, 25.9;ESI-HRMS m/z calcd for C19H21FN2O6S+Na+ 447.0997,found 447.0995.
Product I -21 is yellow solid, yield 84%;Fusing point: 144-145 DEG C of1H NMR(400MHz,CDCl3)δ7.59 (d, J=1.2Hz, 1H), 7.22 (d, J=3.2Hz, 1H), 6.54 (dd, J=3.6,1.6Hz, 1H), 3.74 (s, 3H), 3.72 (s,3H),1.44(s,9H),(2H missing);13C NMR(100MHz,CDCl3)δ164.0,162.9,162.0,151.5, 147.0,146.0,131.9,128.2,115.4,112.6,83.0,53.2,52.4,27.9,25.0;ESI-HRMS m/z calcd for C17H20N2O7S+Na+ 419.0883,found 419.0885.
Product I -22 is yellow solid, yield 51%;Fusing point: 130-131 DEG C of1H NMR(400MHz,CDCl3)δ3.74 (s,3H),3.73(s,3H),1.41(s,9H),1.28(s,9H),(2H missing);13C NMR(100MHz,CDCl3)δ 182.2,164.1,163.1,151.0,82.5,53.2,52.4,39.0,28.0,27.8,24.4,(2C missing);ESI- HRMS m/z calcd for C17H26N2O6S+Na+ 409.1404,found 409.1403.
Product I -23 is yellow solid, yield 52%;Fusing point: 88-89 DEG C of1H NMR(400MHz,CDCl3)δ7.50– 7.46 (m, 2H), 7.40-7.31 (m, 3H), 7.21 (d, J=16.4Hz, 1H), 7.01 (d, J=16.4Hz, 1H), 3.75 (s, 3H),3.72(s,3H),1.45(s,9H),(2H missing);13C NMR(100MHz,CDCl3)δ170.7,164.1, 163.0,151.6,140.3,134.7,131.8,129.8,128.8,128.6,127.5,122.8,83.0,53.2,52.4, 27.9,24.1;ESI-HRMS m/z calcd for C21H24N2O6S+Na+ 455.1247,found 455.1248.
Product I -24 is yellow solid, yield 96%;Fusing point: 56-57 DEG C of1H NMR(400MHz,CDCl3)δ7.88 (d, J=7.6Hz, 2H), 7.47 (t, J=7.6Hz, 1H), 7.40 (t, J=7.6Hz, 2H), 4.22-4.12 (m, 4H), 1.46 (s, 9H), 1.27 (t, J=7.2Hz, 3H), 1.22 (t, J=7.2Hz, 3H), (2H missing);13C NMR(100MHz, CDCl3)δ171.2,163.6,162.6,151.3,133.1,131.6,128.5,127.5,82.8,62.4,61.7,28.0, 26.0,13.8,13.6,(2C missing);ESI-HRMS m/z calcd for C21H26N2O6S+Na+ 457.1404, found 457.1407.
Product II -2 is white solid, yield 79%;Fusing point: 128.0-129.0 DEG C of1H NMR(400MHz,d6- DMSO) δ 7.97 (d, J=9.2Hz, 2H), 7.06 (d, J=8.8Hz, 2H), 5.04 (d, J=14.0Hz, 1H), 4.63 (d, J= 14.0Hz,1H),3.84(s,3H),3.74(s,3H),3.72(s,3H),2.22(s,3H);13C NMR(100MHz,d6-DMSO) δ171.3,170.5,164.1,162.8,162.7,140.3,130.4,127.2,125.9,114.1,55.6,53.6,53.4, 46.7,22.0;ESI-HRMS m/z calcd for C17H18N2O7S+Na+ 417.0727,found 417.0726.
Product II -3 is white solid, yield 78%;Fusing point: 96.0-97.0 DEG C of1H NMR(400MHz,CDCl3)δ 7.80 (d, J=8.0Hz, 2H), 7.28 (d, J=8.0Hz, 2H), 4.46 (d, J=13.2Hz, 1H), 4.27 (d, J= 13.2Hz,1H),3.84(s,6H),2.41(s,3H),2.36(s,3H);13C NMR(100MHz,CDCl3)δ172.4,166.1, 163.1,162.4,143.4,140.6,131.6,129.7,127.8,127.2,53.5,47.8,22.3,21.5,(1C missing);ESI-HRMS m/z calcd for C17H18N2O6S+Na+ 401.0778,found 401.0780.
Product II -4 is white solid, yield 85%;Fusing point: 139.0-139.7 DEG C of1H NMR(400MHz,CDCl3)δ 8.02 (d, J=8.4Hz, 2H), 7.74 (d, J=8.4Hz, 2H), 4.52 (d, J=13.6Hz, 1H), 4.30 (d, J= 13.6Hz,1H),3.85(s,3H),3.84(s,3H),2.38(s,3H);13C NMR(100MHz,CDCl3)δ172.3,165.3, (162.7,162.1,139.8,137.8,133.8 q, J=32.7Hz), 128.8,128.3,125.9 (q, J=3.7Hz), 123.5 (q, J=271.0Hz), 53.6,48.1,22.2, (1C missing);ESI-HRMS m/z calcd for C17H15F3N2O6S+Na+ 455.0495,found 455.0486.
Product II -5 is white solid, yield 78%;Fusing point: 26.2-127.1 DEG C of1H NMR(400MHz,CDCl3)δ 7.97-7.89 (m, 2H), 7.20-7.13 (m, 2H), 4.48 (d, J=13.6Hz, 1H), 4.27 (d, J=13.6Hz, 1H), 3.84(s,3H),3.83(s,3H),2.35(s,3H);13C NMR(100MHz,d6-DMSO)δ171.2,170.6,164.6(d,J =249.6Hz), 164.0,162.7,139.9,131.4 (d, J=2.9Hz), 131.2 (d, J=9.1Hz), 126.1,115.8 (d, J=21.8Hz), 53.6,53.4,47.1,22.1;ESI-HRMS m/z calcd for C16H15FN2O6S+Na+ 405.0527,found 405.0522.
Product II -6 is white solid, yield 72%;Fusing point: 72.0-73.0 DEG C of1H NMR(400MHz,d6-DMSO)δ 7.96-7.92 (m, 2H), 7.61-7.56 (m, 1H), 7.54-7.49 (m, 2H), 5.01 (d, J=14.0Hz, 1H), 4.76 (d, J =14.0Hz, 1H), 3.79 (s, 3H), 3.75 (s, 3H), 1.45 (s, 9H);13C NMR(100MHz,d6-DMSO)δ170.9, 164.1,163.1,149.7,140.0,134.8,132.1,128.7,128.3,126.0,84.8,53.6,47.2,27.5,(1C missing);ESI-HRMS m/z calcd for C19H22N2O7S+Na+ 445.1040,found 445.1039.
Product II -7 is white solid, yield 69%;Fusing point: 75-76 DEG C of1H NMR(400MHz,d6-DMSO)δ7.90 (d, J=8.8Hz, 2H), 7.05 (d, J=8.8Hz, 2H), 4.95 (d, J=14.0Hz, 1H), 4.66 (d, J=13.6Hz, 1H),3.83(s,3H),3.78(s,3H),3.74(s,3H),1.44(s,9H);13C NMR(100MHz,d6-DMSO)δ169.9, 164.1,163.1,162.5,149.8,140.5,130.2,127.3,125.6,114.1,84.6,55.6,54.9,53.5, 46.9,27.5;ESI-HRMS m/z calcd for C20H24N2O8S+Na+ 475.1146,found 475.1148.
Product II -8 is white solid, yield 62%;Fusing point: 69-70 DEG C of1H NMR(400MHz,d6-DMSO)δ7.84 (d, J=8.4Hz, 2H), 7.31 (d, J=8.0Hz, 2H), 4.94 (d, J=14.0Hz, 1H), 4.68 (d, J=14.0Hz, 1H),3.80(s,3H),3.75(s,3H),2.36(s,3H),1.45(s,9H);13C NMR(100MHz,d6-DMSO)δ170.5, 164.1,163.1,149.7,142.4,140.2,132.2,129.2,128.2,125.9,84.7,53.5(2C),47.1, 27.5,21.0;ESI-HRMS m/z calcd for C20H24N2O7S+Na+ 459.1196,found 459.1197.
Product II -9 is white solid, yield 67%;Fusing point: 78-79 DEG C of1H NMR(400MHz,d6-DMSO)δ8.13 (d, J=8.4Hz, 2H), 7.87 (d, J=8.4Hz, 2H), 5.05 (d, J=14.0Hz, 1H), 4.79 (d, J=14.0Hz, 1H),3.80(s,3H),3.75(s,3H),1.45(s,9H);13C NMR(100MHz,d6-DMSO)δ170.1,164.0, (163.0,149.7,139.8,138.7,131.8 q, J=31.9Hz), 129.1,126.6,125.6 (q, J=3.6Hz), 123.9 (q, J=270.8Hz), 85.2,53.7,47.5,27.5, (1C missing);ESI-HRMS m/z calcd for C20H21F3N2O7S+Na+ 513.0914,found 513.0915.
Product II -10 is white solid, yield 72%;Fusing point: 67-68 DEG C of1H NMR(400MHz,d6-DMSO)δ 8.00 (dd, J=8.8,5.6Hz, 2H), 7.34 (dd, J=8.8,8.8Hz, 2H), 4.99 (d, J=13.6Hz, 1H), 4.73 (d, J=14.0Hz, 1H), 3.80 (s, 3H), 3.75 (s, 3H), 1.45 (s, 9H);13C NMR(100MHz,d6-DMSO)δ 170.0,164.5 (d, J=249.6Hz), 164.0,163.0,149.7,140.1,131.5 (d, J=2.9Hz), 131.0 (d, J =9.0Hz), 126.0,115.8 (d, J=21.8Hz), 84.9,53.6,47.2,27.5, (1C missing);ESI-HRMS m/z calcd for C19H21FN2O7S+Na+ 463.0946,found 463.0949.
Product II -11 is white solid, yield 73%;Fusing point: 72-73 DEG C of1H NMR(400MHz,d6-DMSO)δ 8.32 (d, J=9.2Hz, 2H), 8.17 (d, J=8.8Hz, 2H), 5.07 (d, J=14.0Hz, 1H), 4.82 (d, J= 14.0Hz,1H),3.81(s,3H),3.77(s,3H),1.46(s,9H);13C NMR(100MHz,d6-DMSO)δ169.6, 163.9,162.9,149.6,149.3,140.5,139.5,129.6,126.9,123.7,85.2,53.6(2C),47.6, 27.5;ESI-HRMS m/z calcd for C19H21N3O9S+Na+ 490.0891,found 490.0892.
Product II -12 is white solid, yield 78%;Fusing point: 77-78 DEG C of1H NMR(400MHz,d6-DMSO)δ 7.98 (d, J=0.8Hz, 1H), 7.41 (d, J=3.6Hz, 1H), 6.72 (dd, J=3.2,1.6Hz, 1H), 4.76 (d, J= 14.0Hz, 1H), 4.69 (d, J=13.6Hz, 1H), 3.78 (s, 3H), 3.74 (s, 3H), 1.43 (s, 9H);13C NMR (100MHz,d6-DMSO)δ164.1,163.1,160.0,149.8,149.2,147.8,140.5,126.3,119.8,113.0, 84.9,53.6,47.0,27.5,(1C missing);ESI-HRMS m/z calcd for C17H20N2O8S+Na+ 435.0833,found 435.0832.
Product II -13 is white solid, yield 78%;Fusing point: 58-59 DEG C of1H NMR(400MHz,d6-DMSO)δ 4.46 (d, J=13.2Hz, 1H), 4.37 (d, J=13.6Hz, 1H), 3.76 (s, 3H), 3.74 (s, 3H), 1.41 (s, 9H), 1.16(s,9H);13C NMR(100MHz,d6-DMSO)δ180.2,164.0,163.0,149.5,140.0,124.7,84.4, 53.4,46.6,38.5,27.5,27.1,(1C missing);ESI-HRMS m/z calcd for C17H26N2O7S+Na+ 425.1353,found 425.1354.
Product II -14 is white solid, yield 74%;Fusing point: 87-88 DEG C of1H NMR(400MHz,d6-DMSO)δ 7.67 (d, J=6.4Hz, 2H), 7.56 (d, J=16.4Hz, 1H), 7.47-7.40 (m, 3H), 7.15 (d, J=16.4Hz, 1H), 4.84 (d, J=13.6Hz, 1H), 4.57 (d, J=14.0Hz, 1H), 3.78 (s, 3H), 3.74 (s, 3H), 1.43 (s, 9H);13C NMR(100MHz,d6-DMSO)δ170.1,164.1,163.1,149.9,143.2,140.2,135.1,130.3, 129.1,128.1,126.7,125.6,84.9,53.6,45.7,27.6,(1C missing);ESI-HRMS m/z calcd for C21H24N2O7S+Na+ 471.1196,found 471.1196.
Product II -15 is white solid, yield 69%;Fusing point: 62-63 DEG C of1H NMR(400MHz,d6-DMSO)δ 7.94 (d, J=7.2Hz, 2H), 7.58 (t, J=7.2Hz, 1H), 7.51 (t, J=7.2Hz, 2H), 4.96 (d, J=14.0Hz, 1H), 4.71 (d, J=14.0Hz, 1H), 4.32-4.12 (m, 4H), 1.46 (s, 9H), 1.26 (t, J=7.2Hz, 3H), 1.20 (t, J=7.2Hz, 3H);13C NMR(100MHz,d6-DMSO)δ170.9,163.6,162.4,149.9,140.0,134.9, 132.1,128.7,128.3,126.6,84.7,62.8,62.6,47.3,27.6,13.7,13.6;ESI-HRMS m/z calcd for C21H26N2O7S+Na+ 473.1353,found 473.1353.
Product III -2 is white solid, yield 69%;Fusing point: 199.3-199.6 DEG C of1H NMR(400MHz,CDCl3)δ 7.95 (d, J=8.8Hz, 2H), 7.00 (d, J=9.2Hz, 2H), 4.70 (s, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 3.84 (s,3H),2.33(s,3H);13C NMR(100MHz,CDCl3)δ172.7,163.7,162.5,161.9,160.5,143.0, 130.3,126.1,124.0,114.6,55.6,54.2,53.7,53.7,22.4;ESI-HRMS m/z calcd for C17H18N2O8S+H+ 433.0676,found 433.0669.
Product III -3 is white solid, yield 72%;Fusing point: 212.2-212.6 DEG C of1H NMR(400MHz,CDCl3)δ 7.88 (d, J=8.4Hz, 2H), 7.32 (d, J=8.0Hz, 2H), 4.72 (s, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 2.44 (s,3H),2.34(s,3H);13C NMR(100MHz,d6-DMSO)δ172.2,164.9,161.8,160.3,143.6,140.9, 129.6,129.2,128.7,126.6,54.1,53.8,53.7,22.0,21.1;ESI-HRMS m/z calcd for C17H18N2O7S+Na+ 417.0727,found 417.0722.
Product III -4 is white solid, yield 66%;Fusing point: 130.0-131.0 DEG C of1H NMR(400MHz,CDCl3)δ 8.11 (d, J=8.4Hz, 2H), 7.80 (d, J=8.4Hz, 2H), 4.76 (s, 2H), 3.88 (s, 3H), 3.85 (s, 3H), 2.37 (s,3H);13C NMR(100MHz,CDCl3) δ 172.5,161.8,161.7,160.2,142.3,135.1,134.4 (q, J= 33.0Hz), 128.7,126.6,126.1 (q, J=3.4Hz), 124.8 (q, J=271.2Hz), 54.5,53.9,53.9, 22.4;ESI-HRMS m/z calcd for C17H15F3N2O7S+Na+ 471.0444,found 471.0438.
Product III -5 is white solid, yield 62%;Fusing point: 189.1-189.6 DEG C of1H NMR(400MHz,CDCl3)δ 8.05-7.99(m,2H),7.25-7.18(m,2H),4.72(s,2H),3.86(s,3H),3.84(s,3H),2.34(s,3H);13C NMR(100MHz,d6- DMSO) δ 172.2,165.0 (d, J=250.9Hz), 164.2,161.8,160.2,140.8, 131.5 (d, J=9.3Hz), 128.5 (d, J=2.9Hz), 126.6,116.2 (d, J=21.9Hz), 54.2,53.8,53.7, 22.1;ESI-HRMS m/z calcd for C16H15FN2O7S+Na+ 421.0476,found 421.0473.
Product III -6 is white solid, yield 70%;Fusing point: 80.2-80.9 DEG C of1H NMR(400MHz,CDCl3)δ 7.98 (d, J=7.2Hz, 2H), 7.56 (t, J=7.2Hz, 1H), 7.47 (t, J=7.2Hz, 2H), 4.76 (s, 2H), 3.86 (s,3H),3.84(s,3H),1.52(s,9H);13C NMR(100MHz,CDCl3)δ163.9,162.1,160.4,150.1, 142.7,132.7,132.1,128.9,128.4,125.5,86.5,55.1,53.7,53.6,27.7;ESI-HRMS m/z calcd for C19H22N2O8S+Na+ 461.0989,found 461.0985.
Product III -7 is white solid, yield 69%;Fusing point: 153-154 DEG C of1H NMR(400MHz,(CD3)2CO)δ 7.95 (s, 1H), 7.59 (d, J=3.6Hz, 1H), 6.78 (dd, J=3.6,1.6Hz, 1H), 5.16 (s, 2H), 3.86 (s, 3H),3.79(s,3H),1.48(s,9H);13C NMR(100MHz,(CD3)2CO)δ163.3,161.4,155.9,151.1, 149.1,148.3,142.8,128.3,120.1,113.9,86.1,55.2,54.1,53.9,28.0;ESI-HRMS m/z calcd for C17H20N2O9S+Na+ 451.0782,found 451.0781.
Product III -8 is white solid, yield 71%;Fusing point: 136-137 DEG C of1H NMR(400MHz,CDCl3)δ 7.57-7.53 (m, 2H), 7.45-7.38 (m, 4H), 7.11 (d, J=16.4Hz, 1H), 4.62 (s, 2H), 3.86 (s, 3H), 3.85(s,3H),1.52(s,9H);13C NMR(100MHz,CDCl3)δ163.7,162.1,160.4,150.2,143.8, 142.9,134.4,130.6,129.0,128.2,128.1,126.5,122.4,86.6,53.8,53.7,27.8;ESI-HRMS m/z calcd for C21H24N2O8S+Na+ 487.1146,found 487.1144.
Product III -9 is white solid, yield 68%;Fusing point: 78-79 DEG C of1H NMR(400MHz,CDCl3)δ4.34 (s,2H),3.85(s,3H),3.84(s,3H),1.47(s,9H),1.30(s,9H);13C NMR(100MHz,CDCl3)δ 174.7,162.1,160.5,150.0,141.8,125.6,85.9,54.3,53.7,53.5,39.4,27.8,27.7;ESI- HRMS m/z calcd for C17H26N2O8S+Na+ 441.1302,found 441.1299.
Finally, it should be noted that the foregoing is only a preferred embodiment of the present invention, it is not intended to restrict the invention, Although the present invention is described in detail referring to the foregoing embodiments, for those skilled in the art, still may be used To modify the technical solutions described in the foregoing embodiments or equivalent replacement of some of the technical features. It is all within the contents of the present invention and principle, any modification, equivalent replacement, improvement and so on should be included in of the invention Within protection scope.

Claims (8)

1.2,5- dihydros-Isosorbide-5-Nitrae, 5- sulphur phenodiazine Zhuo and its oxide, which is characterized in that structure 2,5- bis- as shown in I in formula 1 Hydrogen -1,4,5- sulphur phenodiazine Zhuo, II and III are the oxidation product of 2,5- dihydro -1,4,5- sulphur phenodiazine Zhuo.
Wherein: R1For substituted aryl substituent group, (replace on phenyl ring includes 4- methoxyl group, 4- methyl, 4- nitro, 4- cyano, 4- trifluoro Methyl, 4- fluorine, 4- chlorine, 4- bromine) 1- naphthyl substituted base, 2- furyl substituent, alkyl substituent, alkenyl group;R2For acetyl Base or tertbutyloxycarbonyl substituent group;R3For methyl substituents or ethyl substituent.
2. 2,5- dihydro-Isosorbide-5-Nitrae according to claim 1,5- sulphur phenodiazine Zhuo and its oxide, which is characterized in that in formula 1 Shown in I, heptatomic ring contain there are three it is heteroatomic simultaneously, also containing there are four different types of substituent group, and the analog derivative can be with The product II and III of different oxidation state is obtained by the oxidation of controllability.
3. 2,5- dihydro-Isosorbide-5-Nitrae described in claim 1,5- sulphur phenodiazine Zhuo and its oxide, which is characterized in that preparation method is such as Shown in formula 2:
The preparation method of target compound I: compound shown in compound shown in general formulae IV, general formula V and powdered sodium carbonate are existed It is dissolved in dichloromethane solvent under room temperature, reactant IV disappears completely, has removing under reaction mixture reduced pressure Solvent, column chromatographic elution obtain target compound I, and X is bromine or chlorine.
4. 2,5- dihydro-Isosorbide-5-Nitrae described in claim 1,5- sulphur phenodiazine Zhuo and its oxide, which is characterized in that target compound II preparation method: i.e. by m-CPBA, that is, metachloroperbenzoic acid of compound shown in general formula I and appropriate equivalent, in room temperature condition Under be dissolved in dichloromethane solvent, reactant I disappears completely, and organic solvent, column will be removed under reaction mixture reduced pressure Chromatographic elution obtains target compound II.
5. 2,5- dihydro-Isosorbide-5-Nitrae described in claim 1,5- sulphur phenodiazine Zhuo and its oxide, which is characterized in that target compound III preparation method: compound shown in general formula I and appropriate excessive m-CPBA are dissolved in methylene chloride at room temperature In solvent, reactant I disappears completely, and organic solvent will be removed under reaction mixture reduced pressure, and column chromatographic elution obtains target Compound III.
6. according to the dihydro of 2,5- described in claim 3-5-Isosorbide-5-Nitrae, the preparation method of 5- sulphur phenodiazine Zhuo and its oxide, feature It is the alkali for using inorganic reagent sodium carbonate as reaction, using methylene chloride as reaction dissolvent, reacts under room temperature Obtain target compound I;Use m-CPBA as oxidant, using methylene chloride as reaction dissolvent, is aoxidized only by control The addition equivalent of agent, reaction can respectively obtain the target compound II and III of different oxidation state under room temperature.
7. according to the dihydro of 2,5- described in claim 3-5-Isosorbide-5-Nitrae, the preparation method of 5- sulphur phenodiazine Zhuo and its oxide, feature The molar ratio for being compounds Ⅳ, compound V and carbonate reagent is IV: V: sodium carbonate=1.0:1.5:2.0, methylene chloride Solution concentration is 0.1M, i.e., 0.1 mole every liter can be obtained target compound I;Chemical compounds I, m-CPBA molar ratio be I: m- CPBA=1.0:1.0, dichloromethane solution concentration are that target compound II can be obtained in 0.15M;Chemical compounds I, m-CPBA rub , than being I: m-CPBA=1.0:3.0, dichloromethane solution concentration is that target compound III can be obtained in 0.15M for you.
8. according to the dihydro of 2,5- described in claim 3-5-Isosorbide-5-Nitrae, the preparation method of 5- sulphur phenodiazine Zhuo and its oxide, feature It is that eluent used in silica gel column chromatography is the mixed solvent of petroleum ether and ethyl acetate, and volume ratio VPetroleum ether:VEthyl acetate=5: Target compound I can be obtained in 1~2:1;Eluent used in silica gel column chromatography is the mixed solvent of petroleum ether and ethyl acetate, And volume ratio VPetroleum ether:VEthyl acetateTarget compound II can be obtained in=3:1~1:1;Eluent used in silica gel column chromatography is petroleum The mixed solvent of ether and ethyl acetate, and volume ratio VPetroleum ether:VEthyl acetateTarget compound III can be obtained in=10:1~3:1.
CN201910258698.XA 2019-04-01 2019-04-01 2,5- dihydro -1,4,5- sulphur phenodiazine Zhuo and its oxide preparation method Pending CN110041290A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910258698.XA CN110041290A (en) 2019-04-01 2019-04-01 2,5- dihydro -1,4,5- sulphur phenodiazine Zhuo and its oxide preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910258698.XA CN110041290A (en) 2019-04-01 2019-04-01 2,5- dihydro -1,4,5- sulphur phenodiazine Zhuo and its oxide preparation method

Publications (1)

Publication Number Publication Date
CN110041290A true CN110041290A (en) 2019-07-23

Family

ID=67275783

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910258698.XA Pending CN110041290A (en) 2019-04-01 2019-04-01 2,5- dihydro -1,4,5- sulphur phenodiazine Zhuo and its oxide preparation method

Country Status (1)

Country Link
CN (1) CN110041290A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111484476A (en) * 2020-04-13 2020-08-04 深圳职业技术学院 3-hydro-1, 2-dithio-2, 2-dioxide and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017160139A (en) * 2016-03-08 2017-09-14 国立大学法人名古屋大学 Production method for bi(hetero)aryl(thio)ether compound
CN110156815A (en) * 2019-06-04 2019-08-23 兰州大学 12a hydrogen-benzo [f] pyridine [1,2-d] [1,4] sulphur nitrogen Zhuo and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017160139A (en) * 2016-03-08 2017-09-14 国立大学法人名古屋大学 Production method for bi(hetero)aryl(thio)ether compound
CN110156815A (en) * 2019-06-04 2019-08-23 兰州大学 12a hydrogen-benzo [f] pyridine [1,2-d] [1,4] sulphur nitrogen Zhuo and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIN CHENG等: "Pyridinium 1,4-zwitterionix thiolates as a useful class of sulfur-containing synthons:application to the synthesis of 2,5-dihydro-1,4,5-thiadiazepines", 《CHEMCOMM》 *
BIN CHENG等: "Switchable Ring-Contractive Extrusion Reactions of 2,5-Dihydro-1,4,5-thiadiazepine S-Oxides:Entries to Pyridazines or Pyrazoles", 《THE JOURNAL OF ORGANIC CHEMISTRY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111484476A (en) * 2020-04-13 2020-08-04 深圳职业技术学院 3-hydro-1, 2-dithio-2, 2-dioxide and preparation method thereof
CN111484476B (en) * 2020-04-13 2021-06-22 深圳职业技术学院 3-hydro-1, 2-dithio-2, 2-dioxide and preparation method thereof

Similar Documents

Publication Publication Date Title
CN106608788B (en) A kind of preparation method of mild diazomethane derivative
CN105175328B (en) It is a kind of using aromatic amine, aromatic aldehyde, ketone synthesis of quinoline derivatives method
CN110240568A (en) Three replace pyridazine analog derivative and preparation method thereof
CN106928201A (en) The method for synthesizing 2 vinyl indole derivativeses
CN109438264A (en) A kind of polysubstituted indenes amine derivative and preparation method thereof
CN110041290A (en) 2,5- dihydro -1,4,5- sulphur phenodiazine Zhuo and its oxide preparation method
CN107382820A (en) A kind of synthetic method of 3 arylisoindole derivative
CN106188044B (en) A kind of synthetic method of 3- arylthios imidazo [1,5-a] N- heterocyclic compounds of catalysis of iodine
CN113234037B (en) Z-2- (2-acylmethylene) thiazolidine-4-ketone derivative and preparation method and application thereof
CN105218540B (en) A kind of preparation method of 3 thiocarbamoyl imidazoles of C simultaneously [1,2 a] pyridine compounds and their
WO2022206010A1 (en) Simple preparation method for isoxazolines
CN104326892A (en) Synthetic method of indanone by gold-catalysis
WO2019168874A1 (en) Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110156815A (en) 12a hydrogen-benzo [f] pyridine [1,2-d] [1,4] sulphur nitrogen Zhuo and preparation method thereof
CN106188046A (en) The synthetic method of 3 arylthio imidazos [1,5 a] the N heterocyclic compound that a kind of iodine promotes
CN107739317A (en) A kind of preparation method and applications of perfluoroalkyl diazomethane
CN108610275A (en) A kind of synthetic method of 3- (2- vinyls) indole derivatives
JP2007238540A (en) Method for producing optically active alcohol compound
CN110028451A (en) A kind of full substituted pyrazole derivative preparation method
Zhou et al. Multicomponent Selective Thioetherification of KSAc: Easy Access to Symmetrical/Unsymmetrical 4‐Alkylthio‐3‐halo‐2 (5H)‐furanones
CN108218840A (en) A kind of synthetic method of bisindole derivatives
Dubbaka et al. Copper-Mediated Oxidative Trifluoromethylthiolation of Potassium Aryltrifluoroborates with Elemental Sulfur and Ruppert–Prakash Reagent
CN104016872B (en) A kind of synthetic method of chiral alpha-non-natural amino acid
CN110240572B (en) Synthesis method of trans-1, 1-cyclopropane dicarboxylic acid ester
CN106854191B (en) 2- 3- methylene -2,3-dihydrofuran synthetic methods containing chiral quaternary carbon center

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190723

RJ01 Rejection of invention patent application after publication